TY - JOUR
T1 - Intensive symptom control of opioid-refractory dyspnea in congestive heart failure
T2 - Role of milrinone in the palliative care unit
AU - Silvestre, Julio
AU - Montoya, Maria
AU - Bruera, Eduardo
AU - Elsayem, Ahmed
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2015/12/1
Y1 - 2015/12/1
N2 - OBJECTIVE: We describe an exemplary case of congestive heart failure (CHF) symptoms controlled with milrinone. We also analyze the benefits and risks of milrinone administration in an unmonitored setting.METHOD: We describe the case of a patient with refractory leukemia and end-stage CHF who developed severe dyspnea after discontinuation of milrinone. At that point, despite starting opioids, she had been severely dyspneic and anxious, requiring admission to the palliative care unit (PCU) for symptom control. After negotiation with hospital administrators, milrinone was administered in an unmonitored setting such as the PCU. A multidisciplinary team approach was also provided.RESULTS: Milrinone produced a dramatic improvement in the patient's symptom scores and performance status. The patient was eventually discharged to home hospice on a milrinone infusion with excellent symptom control.SIGNIFICANCE OF RESULTS: This case suggests that milrinone may be of benefit for short-term inpatient administration for dyspnea management, even in unmonitored settings and consequently during hospice in do-not-resuscitate (DNR) patients. This strategy may reduce costs and readmissions to the hospital related to end-stage CHF.
AB - OBJECTIVE: We describe an exemplary case of congestive heart failure (CHF) symptoms controlled with milrinone. We also analyze the benefits and risks of milrinone administration in an unmonitored setting.METHOD: We describe the case of a patient with refractory leukemia and end-stage CHF who developed severe dyspnea after discontinuation of milrinone. At that point, despite starting opioids, she had been severely dyspneic and anxious, requiring admission to the palliative care unit (PCU) for symptom control. After negotiation with hospital administrators, milrinone was administered in an unmonitored setting such as the PCU. A multidisciplinary team approach was also provided.RESULTS: Milrinone produced a dramatic improvement in the patient's symptom scores and performance status. The patient was eventually discharged to home hospice on a milrinone infusion with excellent symptom control.SIGNIFICANCE OF RESULTS: This case suggests that milrinone may be of benefit for short-term inpatient administration for dyspnea management, even in unmonitored settings and consequently during hospice in do-not-resuscitate (DNR) patients. This strategy may reduce costs and readmissions to the hospital related to end-stage CHF.
KW - Congestive heart failure
KW - Milrinone
KW - Opioid-refractory dyspnea
KW - Palliative care
UR - http://www.scopus.com/inward/record.url?scp=85028237611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028237611&partnerID=8YFLogxK
U2 - 10.1017/S1478951514000935
DO - 10.1017/S1478951514000935
M3 - Article
C2 - 25908519
AN - SCOPUS:85028237611
SN - 1478-9515
VL - 13
SP - 1781
EP - 1785
JO - Palliative & supportive care
JF - Palliative & supportive care
IS - 6
ER -